Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has earned a consensus recommendation of “Buy” from the twelve brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $45.67.
Several equities research analysts recently weighed in on ADMS shares. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 target price on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. Mizuho restated a “buy” rating and set a $48.00 target price (up from $26.00) on shares of Adamas Pharmaceuticals in a report on Wednesday, September 13th. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Adamas Pharmaceuticals in a report on Sunday, September 17th. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter worth approximately $110,000. Quantbot Technologies LP bought a new position in Adamas Pharmaceuticals during the 3rd quarter valued at approximately $119,000. Tower Research Capital LLC TRC bought a new position in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $109,000. Sei Investments Co. increased its position in Adamas Pharmaceuticals by 1,105.0% during the 3rd quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after buying an additional 8,033 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new position in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $184,000. Institutional investors and hedge funds own 79.40% of the company’s stock.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.03). Adamas Pharmaceuticals’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.66) earnings per share. analysts expect that Adamas Pharmaceuticals will post -3.84 EPS for the current year.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.